Summary
40 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Revenue grew by 14% a year over the last 3 years.
What to watch
- It earns only 0.3 CHF a year on every 100 CHF of invested capital.
- Out of every 100 CHF of revenue, only 3.1 CHF is left as net profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 141.7 CHF for 1 CHF of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (CHF)
Diluted EPS (CHF)
- Analyst estimate
Revenue grew by 16% a year over 5 years. Over the last 3 years it grew by 14% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 CHF of revenue goes
- Cost of sales 23 CHF
- Research and development 11 CHF
- Sales and administration 65 CHF
- Taxes and other -3.3 CHF
- Net profit 4.9 CHF
Net profit, industry median (Medical - Devices) 6.9 CHF
Out of every 100 CHF of revenue, 4.9 CHF is left as net profit.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 162.5 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.